NCT00459862 · REGISTRY CONDITION SEARCH

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2015-02-24

This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression-free Survival Assessed by RECIST

→

outcome · POSTED

Determine the Clinical Toxicities of This Drug in This Participant Population.

→

outcome · POSTED

Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.

→

outcome · POSTED

Overall Response Rate

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed malignant pleural mesothelioma: * Measurable disease * No progressive disease inside or outside of any prior radiation field * No symptomatic, untreated, or uncontrolled CNS metastases * Patients with CNS metastases treated with whole brain radiation (WBRT) may be enrolled after completion of WBRT * Patients may begin study therapy as early as the next day after completion of WBRT * ECOG performance status 0-2 * Life expectancy \>= 12 weeks * ANC \>=1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * WBC \>= 3,000/mm\^3 * Bilirubin =\< 1.5 times upper limit of normal (ULN) * AST and ALT =\< 2.5 times ULN * Alkaline phosphatase =\< 2.5 times ULN * Creatinine =\< 1.5 times ULN or creatinine clearance \>= 50 mL/min * Proteinuria =\< 1+ on 2 consecutive dipsticks taken \>= 1 week apart * No condition that impairs ability to swallow and retain study drug tablets including, but not limited to, any of the following: * Gastrointestinal tract disease resulting in an inability to take oral medication * Requirement for IV alimentation * Prior surgical procedures affecting absorption * Active peptic ulcer disease * No other primary malignancy except for carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence * Patients with a history of low-grade (Gleason score =\< 6) localized prostate cancer are eligible even if diagnosed within the past 5 years * No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study * None of the following concurrent severe and/or uncontrolled medical conditions: * Serious or nonhealing wound, ulcer, or bone fracture * Abdominal fistula, diverticulosis, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * Poorly controlled diabetes * Interstitial pneumonia * Extensive and symptomatic interstitial fibrosis of the lung * No cardiovascular illness or complication, including any of the following: * Any history of cerebrovascular accident within the past 6 months * History of myocardial infarction (prior electrocardiographic evidence of myocardial injury) * History of cardiac arrhythmia (prior electrocardiographic evidence of abnormal heart rhythm) * Admission for unstable angina * Cardiac angioplasty or stenting within the past 12 months * NYHA class III-IV heart failure * Asymptomatic NYHA class II heart failure allowed * QTc prolongation (defined as a QTc interval ≥ 500 msecs) or other significant electrocardiogram abnormalities * Venous thrombosis within the past 12 weeks * No ancillary therapy considered investigational within the past 4 weeks * No symptomatic, untreated, or uncontrolled seizure disorder * No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit study compliance * No significant traumatic injury within the past 4 weeks * No more than 1 prior systemic therapy for malignant pleural mesothelioma * No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks * Insertion of a vascular access device is not considered major or minor surgery * No minor surgery within the past 2 weeks * Insertion of a vascular access device is not considered major or minor surgery * Prior palliative radiotherapy allowed * No prior palliative radiotherapy to the chest except for a maximum of 3 fractions of radiotherapy for superior vena cava syndrome * No concurrent therapeutic warfarin * Low molecular-weight heparin or prophylactic low-dose warfarin allowed * No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy * No concurrent medications that act through the CYP450 system * No concurrent combination antiretroviral therapy for HIV-positive patients * PT/INR/PTT =\< 1.2 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective nonhormonal contraception * No uncontrolled infection * No uncontrolled blood pressure (BP) (defined as systolic BP \> 140 mm Hg and/or diastolic BP \> 90 mm Hg in spite of adequate anti-hypertensive therapy) * No other severe underlying disease that, in the judgment of the investigator, would limit study compliance
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
intervention Names
Other: laboratory biomarker analysis
Drug: pazopanib hydrochloride
label
Arm I
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I
description
Correlative study
name
laboratory biomarker analysis
type
OTHER
arm Group Labels
Arm I
description
Given orally
name
pazopanib hydrochloride
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 34
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The proportion of patients who are progression-free at 6 months is calculated by dividing the number of evaluable participants who are progression-free at 6 months based on the Response Evaluation Criteria for Solid Tumors (RECIST) by the total number of evaluable participants.
measure
Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)
time Frame
6 months

secondary Outcomes

measure
Overall Survival
time Frame
From study enrollment to time of death from any cause or censored at last follow-up, up to 3 years
measure
Progression-free Survival Assessed by RECIST
time Frame
From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years
description
The number of participants with a reported Grade 3, Grade 4, and Grade 5 toxicity, regardless of attribution, will be tabulated.
measure
Determine the Clinical Toxicities of This Drug in This Participant Population.
time Frame
Participants will be evaluated every cycle during treatment
description
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.
measure
Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.
time Frame
From study enrollment to the first date of disease progression
description
To evaluate the confirmed response rate of pazopanib in patients with MPM based on the RECIST criteria for MPM. Responses are confirmed by repeat assessments that are be performed no less than 4 weeks after the criteria for response are first met. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
measure
Overall Response Rate
time Frame
Participants will be evaluated every cycle during treatment, up to 2 years

Full study description

brief Summary: This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
detailed Description: PRIMARY OBJECTIVES: I. Determine the effect of pazopanib hydrochloride on the proportion of patients with malignant pleural mesothelioma who are progression-free at 6 months based on the RECIST criteria. II. Determine the clinical toxicities of this drug in this patient population. SECONDARY OBJECTIVES: I. Determine the objective tumor response status in these patients as measured by the RECIST criteria or the modified RECIST criteria. II. Determine the response rate in patients treated with this drug. III. Determine the effect of this drug on overall survival and time to progression in these patients. IV. Assess predictive markers of activity of this drug in these patients. V. Assess serologic markers of target inhibition by this drug in these patients. VI. Determine the clinical toxicities of this drug in this patient population. OUTLINE: This is a multicenter study. Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Blood is collected at baseline and prior to each course of therapy and analyzed for markers of angiogenesis. After completion of study therapy, patients are followed every 3 months.

Source references

references

citation
Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). Oncologist. 2020 Jun;25(6):523-531. doi: 10.1634/theoncologist.2019-0574. Epub 2019 Dec 24.
pmid
31872928
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-61c4318fdfe413d99d37
requested nct id
NCT00459862
primary nct id
NCT00459862
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
payload sha256
158cbb1f52aadca8bd69fae0ebb8ff3e2a9f70d29a360194d3b84058700e9e9a
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-61c4318fdfe413d99d37
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00459862
occurrences
context exact
NCT00459862
end
11
exact text
NCT00459862
start
0
offset unit
unicode_code_points
query cond
Malignant Mesothelioma
query disease state id
ds-malignant-mesothelioma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
source json pointer
/studies/17/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
cea2c8257fd010b5a678c6d881c3895d7caee615053e0864243efc0f4c20095c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice